SAN DIEGO, Oct. 17, 2016 /PRNewswire/ -- Trovagene, Inc.
(NASDAQ: TROV), a developer of circulating tumor DNA (ctDNA)
molecular diagnostics, today announced that its Chief Executive
Officer, Bill Welch, will present a
corporate overview at the BIO Investor Forum taking place
October 18-19, 2016 at the Westin St.
Francis Hotel, San Francisco,
CA.
Trovagene is scheduled to present on Wednesday, October 19, 2016 at 2:00 pm PDT. The Company's Chief Executive
Officer, Bill Welch, and Chief
Scientific Officer, Mark Erlander,
Ph.D., will be available for one-on-one meetings during the
conference. The presentation will be webcast live at
http://www.veracast.com/webcasts/bio/investorforum2016/17220228072.cfm
and can also be accessed through the investor relations web page at
www.trovagene.com. A replay of the presentation will be available
at www.trovagene.com and will be archived for 90 days.
About Trovagene, Inc.
Headquartered in San Diego,
California, Trovagene is leveraging its proprietary
Precision Cancer Monitoring® (PCM) technology for the detection and
monitoring of circulating tumor DNA (ctDNA) in urine. The Company's
technology detects and quantitates oncogene mutations in cancer
patients for improved disease management. Trovagene's PCM
technology is designed to provide important clinical information
beyond the current standard of care, and is protected by
significant intellectual property including multiple issued patents
and pending patent applications globally.
Forward Looking Statements
Certain statements in this press release are forward-looking
within the meaning of the Private Securities Litigation Reform Act
of 1995. These statements may be identified by the use of words
such as "anticipate," "believe," "forecast," "estimated" and
"intend," or other similar terms or expressions that concern
Trovagene's expectations, strategy, plans or intentions. These
forward-looking statements are based on Trovagene's current
expectations and actual results could differ materially. There are
a number of factors that could cause actual events to differ
materially from those indicated by such forward-looking statements.
These factors include, but are not limited to, substantial
competition; our need for additional financing; uncertainties of
patent protection and litigation; clinical trials involve a lengthy
and expensive process with an uncertain outcome, and results of
earlier studies and trials may not be predictive of future trial
results; uncertainties of government or fourth party payer
reimbursement; limited sales and marketing efforts and dependence
upon fourth parties; and risks related to failure to obtain FDA
clearances or approvals and noncompliance with FDA regulations. As
with any medical diagnostic tests under development, there are
significant risks in the development, regulatory approval and
commercialization of new products. There are no guarantees that our
Precision Cancer Monitoring® platform will be utilized
by oncologists or prove to be commercially successful. Trovagene
does not undertake an obligation to update or revise any
forward-looking statement. Investors should read the risk
factors set forth in Trovagene's Form 10-K for the year ended
December 31, 2015 and its other
periodic reports filed with the Securities and Exchange
Commission.
Trovagene
Contacts
|
|
Beth
Anderson
|
Vicki
Kelemen
|
VP, Finance &
Administration
|
Sr. Director,
Marketing Communications
|
858-952-7593
|
858-952-7652
|
ir@trovagene.com
|
vkelemen@trovagene.com
|
Logo -
http://photos.prnewswire.com/prnh/20160520/370471LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/trovagene-to-present-at-the-bio-investor-forum-in-san-francisco-on-october-19-300345824.html
SOURCE Trovagene, Inc.